Astellas Reports P-III Study (SKYLIGHT 1) Results of Fezolinetant for Vasomotor Symptoms Due to Menopause
Shots:
- The P-III study evaluating Fezolinetant (30 & 45mg, qd) vs PBO in a ratio (1:1:1) in 527 patients at 97 facilities across the USA, Canada, Czech Republic, Hungary, Poland, Spain & the UK
- The trial met its 4 coprimary efficacy EPs i.e., the therapy showed an improvement from baseline in VMS frequency & severity @4 & 12wks., improvements were seen as early as 1wk. & the effects were maintained at 52wk. study period, TEAEs (37% & 43% vs 45%). The study results were published in The Lancet
- The safety profile was observed during the 40wk. extension period was consistent with 12wk. PBO-controlled period. The 2EPs were mean change in PROMIS SD SF 8b total score from baseline to 12wks., improvements in sleep disturbance, statistical significance was not met for fezolinetant dose @12wks.
Ref: prnewswire | Image: Astellas
Related Post:- Astellas and Seagen Report the NMPA’s Acceptance of BLA for Enfortumab Vedotin to Treat Urothelial Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
